Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rosuvastatin for ischemia-reperfusion injury after CABG
ACTRN12613000031763Phase 4Not yet recruiting
- Sponsor
- South Australian Health and Medical Research Institute
- Start
- Feb 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rosuvastatin in myocardial ischemia-reperfusion injury (2 arms), sponsored by South Australian Health and Medical Research Institute. Primary endpoint: Myocardial infarct size. Planned start Feb 2013; status: not yet recruiting.
02
Drugs
rosuvastatin
03
Conditions
myocardial ischemia-reperfusion injury
Beyond the preview
Go deeper on ACTRN12613000031763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000031763.